Analyst Notes: These kind of things are troubling because of the cardiovascular nature of the FDA’s qualms. However, give it a 50% success probability “In the second CRL, Amylin and its partners were asked to conduct a thorough QT (tQT) study with Bydureon and submit data from the DURATION-5 study which was conducted to compare […]